-transparent.png){kind=logo}
Intraperitoneal (i.p.) injection and oral (p.o.) gavage were evaluated in the mouse micronucleus test with mitomycin C (MMC). The tests were carried out in 2 laboratories with the MS/Ae and CD-1 mouse strains. On the basis of a small-scale acute toxicity study and a pilot experiment, the full-scale micronucleus test was performed with a 24-h sampling time at doses of 1, 2, 4, and 8 mg/kg for both treatment routes. In both strains, a clear positive dose-response relation was shown by both routes. Although the frequency of micronucleated polychromatic erythrocytes (MNPCEs) was higher with i.p. on a mg/kg basis, this tendency was reversed when dose was expressed as a percentage of the LD50.
S Sato, and
N Inui, and
Y Ikeda, and
Y Hiraga
August 1989,
Mutation research,
S Sato, and
N Inui, and
Y Ikeda, and
Y Hiraga
August 1989,
Mutation research,
S Sato, and
N Inui, and
Y Ikeda, and
Y Hiraga
August 1989,
Mutation research,
S Sato, and
N Inui, and
Y Ikeda, and
Y Hiraga
August 1989,
Mutation research,
S Sato, and
N Inui, and
Y Ikeda, and
Y Hiraga
August 1989,
Mutation research,
S Sato, and
N Inui, and
Y Ikeda, and
Y Hiraga
August 1989,
Mutation research,
S Sato, and
N Inui, and
Y Ikeda, and
Y Hiraga
August 1989,
Mutation research,
S Sato, and
N Inui, and
Y Ikeda, and
Y Hiraga
August 1989,
Mutation research,
S Sato, and
N Inui, and
Y Ikeda, and
Y Hiraga
January 1985,
Cancer immunology, immunotherapy : CII,
S Sato, and
N Inui, and
Y Ikeda, and
Y Hiraga
March 1986,
Gan to kagaku ryoho. Cancer & chemotherapy,
